Baekje Shenzhou Introduces Onsen Pharmaceuticals CDK2 Inhibitors for $1.33 billion
JESUS60
发表于 2023-11-22 11:31:46
1294
0
0
On November 21st, Baekje announced that it had reached a cooperation agreement with Ensem Therapeutics to introduce the CDK2 inhibitor ETX-197, which the latter is about to submit for IND (drug clinical trials).
According to the terms of the agreement, Ensem will receive a down payment and is entitled to additional payments based on specific research and development, registration, and commercialization milestones achieved, with a total transaction amount of $1.33 billion. In addition, Ensem will also have the right to receive graded sales royalties.
Ensem is a pioneering drug research and development company that leverages its unique Kinetic Ensemble& Reg; Develop innovative small molecule precise anticancer therapies on the technology platform. The CDK2 inhibitor ETX-197 is also Ensem's first pipeline.
Senior Vice President of Baekje Shenzhou Dr. Wang Lai, Global R&D Director, stated: "Baekje Shenzhou is committed to developing new molecules to improve the treatment pattern of cancer patients. At present, there is a huge and unmet clinical demand in the field of breast cancer. This cooperation coincides with our strategic focus in the field of breast cancer. Ensem's CDK2 inhibitor complements the CDK4 inhibitor independently developed by the company and in clinical phase 1, which is expected to improve the current CDK4/6 inhibitor in specific breast cancer patients Treatment effect, and strengthen our early research and development pipeline in the field of breast cancer and other solid tumors. We look forward to working with Ensem to promote this molecule into clinical practice in the near future
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
- The Biden administration has finally finalized TSMC's $6.6 billion factory building subsidy, limiting buybacks for the next five years
- BOSS directly repurchases 370000 shares of Class A common stock at $6.69 per share
- Baidu Zhantou leads Quanling in raising millions of dollars in Pre-A round financing
- Citigroup raises NetEase target price to $115 to maintain 'buy' rating
- Qifu Technology's Q3 Financial Report: Newly Added $450 Million Repurchase Plan
- China International Capital Corporation (CICC) maintains its "outperform the industry" rating with a target price of $6.0
- Bitcoin price once hit a new historical high of $95000
- BOSS directly repurchases 368400 shares of Class A common stock at a price of $6.78 per share
- Morgan Stanley: Give Baidu a "synchronized with the market" rating target price of $105
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏